Moligand™, 10 mM in Ethanol Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 5 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla . Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction.
| Isomeric SMILES | C[C@@H]([C@H]1[C@@H](C[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)NC)C)C)O)NC |
|---|---|
| Molecular Weight | 402.364 |
| Reaxy-Rn | 47748950 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=47748950&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Refractive Index | 1.55 |
|---|---|
| Boil Point(°C) | 495.7 °C |
| Melt Point(°C) | 219-222°C |
| 1. Ting Xue, Yaodong Chen, Jia Xu, Weiqin Du, Pengzhou Kong, Xinri Zhang. (2023) Cyclovirobuxine D inhibits growth and progression of non‑small cell lung cancer cells by suppressing the KIF11‑CDC25C‑CDK1‑CyclinB1 G2/M phase transition regulatory network and the NFκB/JNK signaling pathway. INTERNATIONAL JOURNAL OF ONCOLOGY, 62 (5): (1-21). [PMID:36929198] [10.3892/ijo.2023.5505] |
| 2. Fengqi Jiang, Yaodong Chen, Shuo Ren, Zizhuo Li, Kan Sun, Yanwei Xing, Yuekun Zhu, Daxun Piao. (2020) Cyclovirobuxine D inhibits colorectal cancer tumorigenesis via the CTHRC1‑AKT/ERK‑Snail signaling pathway. INTERNATIONAL JOURNAL OF ONCOLOGY, 57 (1): (183-196). [PMID:32319595] [10.3892/ijo.2020.5038] |
| 3. Jiuwei Zhang, Yaodong Chen, Jing Lin, Ruimei Jia, Tingting An, Tianxiu Dong, Yu Zhang, Xiuhua Yang. (2020) Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the EGFR-FAK-AKT/ERK1/2-Slug Signaling Pathway in Human Hepatocellular Carcinoma. DNA AND CELL BIOLOGY, 39 (3): (355-367). [PMID:31913706] [10.1089/dna.2019.4990] |
| 4. Jiang Xinru, Li Hongdan, Liu Yang. (2024) Cyclovirobuxine D inhibits hepatocellular carcinoma growth by inducing ferroptosis of hepatocellular carcinoma cells. Discover Oncology, 15 (1): (1-11). [PMID:38563866] [10.1007/s12672-024-00940-2] |
| 5. Jinku Guo, Yingfeng Cao, Kaipen Jin, Bing Liu, Wei Wang, Chen Chen, Jun Xie, Ankai Xu. (2026) Cyclovirobuxine D suppresses cancer stemness in osteosarcoma with implication of the noncanonical NF-kappaB pathway. Frontiers in Pharmacology, [PMID:] [10.3389/fphar.2026.1746984] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →
